Dendreon (DNDN -1.6%) slips after Maxim downgraded the shares to Sell today, citing concerns...

This news story has 3 comments:

Register or Login to rate comments »

Theodore Cohen Comments (1694)
 
There is NO study on the use of Provenge post-chemo. Provenge is approved prechemo. They put together the fact that Xtandi was only approved post-chemo with the data on the one patient who did well with Provenge after Xtandi to come to that conclusion about the combination. This piece by Maxim is flawed in the extreme. It is totally lacking in an understanding of the underlying fundamentals.
14 Feb, 01:10 PM Reply Like

zappel26 Comments (8)
 
Ted, thanks again for all the killer articles, comments, and so on. Can't believe how much DNDN's stock price was beaten up this week. Anyway, I share the same feeling on the Maxim downgrade.
Absolutely love the science behind DNDN. Would think stock price would get it together at some point. Look forward to next week's CHMP date and early indication on EU approval. Finally, earnings call, too.
Thanks again.
MarianoP
16 Feb, 12:55 AM Reply Like

Theodore Cohen Comments (1694)
 
Hi!

Last week's action was all about options. The stock price will reflect the value behind the science when quarterly revenue reaches $100 million (cashflow breakeven) and COGS drop to 30-40%. That's what the Street is waiting to see.

We already know how 4Q12 shaped up revenue-wise, but one never knows what tidbits might be revealed later this month.

Be well.

Ted
16 Feb, 07:04 AM Reply Like